In this study, we have developed chimaeric RHDV VLP containing epitopes derived from CRC TAAs topIIα and survivin as an immunotherapeutic vaccine in a murine model of CRC, investigating the potential for therapeutic vaccination with a multi-target VLP vaccine. This evidence concerns the gene BIRC5 and colorectal carcinoma.